Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1263 clinical trials
Featured trial
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

urothelial carcinoma
metastatic urothelial carcinoma
bladder cancer
bladder carcinoma
  • 259 views
  • 10 May, 2022
  • 64 locations
Featured trial
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages≥ 2 Years to < 12 Years) With Atopic Dermatitis ((TRuE-AD3)

The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children with Atopic Dermatitis. This is a randomized, double-blind, Vehicle Controlled study. Participants will be randomized 2:2:1 to blinded treatment with ruxolitinib cream 0.75% ,1.5% , or vehicle cream, with stratification by baseline IGA …

  • 52 views
  • 19 Sep, 2022
  • 51 locations
Featured trial
COPD Research Study for those with currently using inhaled medications (triple therapy) and have required an oral steroid for a flare in breathing 1-2 times in the last 12 months.

This investigational study is enrolling moderate to severe COPD subjects.   To qualify you must be on inhaled maintenance medications and have required oral steroids 1-2 times or a hospitalization in the last year.    Pulmonary function test will be performed and compensation will be provided for those who qualify.  

  • 147 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

This is an open-label, randomized (1:1), multicenter, Phase 3 clinical trial evaluating the safety and efficacy of nivolumab in combination with investigational agent sitravatinib compared to docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with …

advanced lung cancer
lung carcinoma
docetaxel
nivolumab
squamous non-small cell lung cancer
  • 543 views
  • 04 May, 2022
  • 143 locations
Featured trial
Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-7)

This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS.

pembrolizumab
KRAS
  • 36 views
  • 12 Sep, 2022
  • 95 locations
Featured trial
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

advanced lung cancer
recurrent non-small cell lung cancer
KRAS
docetaxel
refractory non-small cell lung cancer
  • 34 views
  • 20 Sep, 2022
  • 171 locations
Featured trial
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults Who Are in Early Stages of Treatment for Relapsing Remitting Multiple Sclerosis

A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults Who Are in Early

  • 125 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered

  • 248 views
  • 25 Mar, 2021
  • 1 location
Featured trial
The Effects of a Novel Probiotic Supplement on Menopausal Symptoms

The purpose of this research study is that Lactobacillus brevis HA-112 and Lactobacillus paracasei HA-274, consumed over a 12-week period, will help reduce the symptoms of menopause. &nbsp

  • 269 views
  • 23 Nov, 2020
  • 1 location
Featured trial
ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

ADvance II: A 12-month Double-blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's

cholinesterase
mild dementia
rivastigmine
cholinesterase inhibitors
alzheimer's disease
  • 0 views
  • 22 Nov, 2021
  • 12 locations